(COO) The Cooper Companies - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US2166485019
Stock: Contact Lenses, IUD, Fertility Consumables, Medical Devices
Total Rating 40
Risk 92
Buy Signal 0.20
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 25.8% |
| Relative Tail Risk | -10.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.34 |
| Alpha | -28.55 |
| Character TTM | |
|---|---|
| Beta | 0.812 |
| Beta Downside | 0.668 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.17% |
| CAGR/Max DD | -0.02 |
Description: COO The Cooper Companies January 02, 2026
The Cooper Companies (NASDAQ:COO) operates two distinct businesses: CooperVision, which designs and sells spherical, toric, and multifocal contact lenses for conditions such as astigmatism, presbyopia, and myopia; and CooperSurgical, which provides fertility-related consumables and devices, hormone-free contraception (e.g., the Paragard IUD), and cryostorage services for cord blood and tissue. Both segments distribute through eye-care professionals, hospitals, group purchasing organizations and authorized resellers.
In FY 2023 the company reported roughly $2.5 billion in revenue, with CooperVision contributing about 70 % and CooperSurgical the remainder; the contact-lens market is projected to grow at a 5-6 % CAGR through 2028, driven by rising myopia prevalence and an aging population, while the global fertility-assisted-reproduction market is expanding at ~7 % CAGR as delayed child-bearing becomes more common. A key operating metric is the average selling price (ASP) of lenses, which has risen modestly (≈3 % YoY) as premium multifocal and myopia-control products gain market share.
For a deeper quantitative assessment, you might explore the ValueRay platform’s detailed valuation models.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 374.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.16 > 1.0 |
| NWC/Revenue: 24.28% < 20% (prev 23.84%; Δ 0.44% < -1%) |
| CFO/TA 0.06 > 3% & CFO 796.1m > Net Income 374.9m |
| Net Debt (2.67b) to EBITDA (1.02b): 2.62 < 3 |
| Current Ratio: 1.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (198.1m) vs 12m ago -1.49% < -2% |
| Gross Margin: 64.32% > 18% (prev 0.67%; Δ 6365 % > 0.5%) |
| Asset Turnover: 33.12% > 50% (prev 31.63%; Δ 1.49% > 0%) |
| Interest Coverage Ratio: 5.89 > 6 (EBITDA TTM 1.02b / Interest Expense TTM 109.1m) |
Altman Z'' 4.72
| A: 0.08 (Total Current Assets 2.11b - Total Current Liabilities 1.11b) / Total Assets 12.39b |
| B: 0.62 (Retained Earnings 7.64b / Total Assets 12.39b) |
| C: 0.05 (EBIT TTM 642.1m / Avg Total Assets 12.36b) |
| D: 1.75 (Book Value of Equity 7.26b / Total Liabilities 4.16b) |
| Altman-Z'' Score: 4.72 = AA |
Beneish M -2.93
| DSRI: 1.10 (Receivables 829.0m/717.0m, Revenue 4.09b/3.90b) |
| GMI: 1.04 (GM 64.32% / 66.64%) |
| AQI: 0.96 (AQ_t 0.66 / AQ_t-1 0.69) |
| SGI: 1.05 (Revenue 4.09b / 3.90b) |
| TATA: -0.03 (NI 374.9m - CFO 796.1m) / TA 12.39b) |
| Beneish M-Score: -2.93 (Cap -4..+1) = A |
What is the price of COO shares?
As of February 07, 2026, the stock is trading at USD 82.10 with a total of 1,508,278 shares traded.
Over the past week, the price has changed by +0.88%, over one month by -2.63%, over three months by +18.99% and over the past year by -13.84%.
Over the past week, the price has changed by +0.88%, over one month by -2.63%, over three months by +18.99% and over the past year by -13.84%.
Is COO a buy, sell or hold?
The Cooper Companies has received a consensus analysts rating of 4.05.
Therefore, it is recommended to buy COO.
- StrongBuy: 9
- Buy: 2
- Hold: 8
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the COO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 91.1 | 10.9% |
| Analysts Target Price | 91.1 | 10.9% |
| ValueRay Target Price | 88.4 | 7.6% |
COO Fundamental Data Overview February 04, 2026
P/E Trailing = 43.1283
P/E Forward = 18.0832
P/S = 3.918
P/B = 1.9363
P/EG = 2.1231
Revenue TTM = 4.09b USD
EBIT TTM = 642.1m USD
EBITDA TTM = 1.02b USD
Long Term Debt = 2.46b USD (from longTermDebt, last quarter)
Short Term Debt = 85.6m USD (from shortTermDebt, last quarter)
Debt = 2.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.67b USD (from netDebt column, last quarter)
Enterprise Value = 18.71b USD (16.03b + Debt 2.78b - CCE 110.6m)
Interest Coverage Ratio = 5.89 (Ebit TTM 642.1m / Interest Expense TTM 109.1m)
EV/FCF = 43.13x (Enterprise Value 18.71b / FCF TTM 433.7m)
FCF Yield = 2.32% (FCF TTM 433.7m / Enterprise Value 18.71b)
FCF Margin = 10.60% (FCF TTM 433.7m / Revenue TTM 4.09b)
Net Margin = 9.16% (Net Income TTM 374.9m / Revenue TTM 4.09b)
Gross Margin = 64.32% ((Revenue TTM 4.09b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 56.42% (prev 65.26%)
Tobins Q-Ratio = 1.51 (Enterprise Value 18.71b / Total Assets 12.39b)
Interest Expense / Debt = 0.88% (Interest Expense 24.4m / Debt 2.78b)
Taxrate = 27.57% (32.2m / 116.8m)
NOPAT = 465.1m (EBIT 642.1m * (1 - 27.57%))
Current Ratio = 1.89 (Total Current Assets 2.11b / Total Current Liabilities 1.11b)
Debt / Equity = 0.34 (Debt 2.78b / totalStockholderEquity, last quarter 8.24b)
Debt / EBITDA = 2.62 (Net Debt 2.67b / EBITDA 1.02b)
Debt / FCF = 6.16 (Net Debt 2.67b / FCF TTM 433.7m)
Total Stockholder Equity = 8.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.03% (Net Income 374.9m / Total Assets 12.39b)
RoE = 4.54% (Net Income TTM 374.9m / Total Stockholder Equity 8.25b)
RoCE = 6.00% (EBIT 642.1m / Capital Employed (Equity 8.25b + L.T.Debt 2.46b))
RoIC = 4.32% (NOPAT 465.1m / Invested Capital 10.78b)
WACC = 7.69% (E(16.03b)/V(18.82b) * Re(8.91%) + D(2.78b)/V(18.82b) * Rd(0.88%) * (1-Tc(0.28)))
Discount Rate = 8.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF Debug] Terminal Value 76.86% ; FCFF base≈375.5m ; Y1≈321.2m ; Y5≈249.0m
Fair Price DCF = 10.90 (EV 4.81b - Net Debt 2.67b = Equity 2.14b / Shares 196.0m; r=7.69% [WACC]; 5y FCF grow -17.55% → 2.90% )
EPS Correlation: -84.43 | EPS CAGR: -59.55% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.26 | Revenue CAGR: 8.40% | SUE: 0.30 | # QB: 0
EPS next Quarter (2026-04-30): EPS=1.07 | Chg30d=-0.001 | Revisions Net=+1 | Analysts=17
EPS current Year (2026-10-31): EPS=4.51 | Chg30d=-0.001 | Revisions Net=+1 | Growth EPS=+9.4% | Growth Revenue=+5.5%
EPS next Year (2027-10-31): EPS=4.96 | Chg30d=+0.013 | Revisions Net=+2 | Growth EPS=+10.0% | Growth Revenue=+5.4%
P/E Forward = 18.0832
P/S = 3.918
P/B = 1.9363
P/EG = 2.1231
Revenue TTM = 4.09b USD
EBIT TTM = 642.1m USD
EBITDA TTM = 1.02b USD
Long Term Debt = 2.46b USD (from longTermDebt, last quarter)
Short Term Debt = 85.6m USD (from shortTermDebt, last quarter)
Debt = 2.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.67b USD (from netDebt column, last quarter)
Enterprise Value = 18.71b USD (16.03b + Debt 2.78b - CCE 110.6m)
Interest Coverage Ratio = 5.89 (Ebit TTM 642.1m / Interest Expense TTM 109.1m)
EV/FCF = 43.13x (Enterprise Value 18.71b / FCF TTM 433.7m)
FCF Yield = 2.32% (FCF TTM 433.7m / Enterprise Value 18.71b)
FCF Margin = 10.60% (FCF TTM 433.7m / Revenue TTM 4.09b)
Net Margin = 9.16% (Net Income TTM 374.9m / Revenue TTM 4.09b)
Gross Margin = 64.32% ((Revenue TTM 4.09b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 56.42% (prev 65.26%)
Tobins Q-Ratio = 1.51 (Enterprise Value 18.71b / Total Assets 12.39b)
Interest Expense / Debt = 0.88% (Interest Expense 24.4m / Debt 2.78b)
Taxrate = 27.57% (32.2m / 116.8m)
NOPAT = 465.1m (EBIT 642.1m * (1 - 27.57%))
Current Ratio = 1.89 (Total Current Assets 2.11b / Total Current Liabilities 1.11b)
Debt / Equity = 0.34 (Debt 2.78b / totalStockholderEquity, last quarter 8.24b)
Debt / EBITDA = 2.62 (Net Debt 2.67b / EBITDA 1.02b)
Debt / FCF = 6.16 (Net Debt 2.67b / FCF TTM 433.7m)
Total Stockholder Equity = 8.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.03% (Net Income 374.9m / Total Assets 12.39b)
RoE = 4.54% (Net Income TTM 374.9m / Total Stockholder Equity 8.25b)
RoCE = 6.00% (EBIT 642.1m / Capital Employed (Equity 8.25b + L.T.Debt 2.46b))
RoIC = 4.32% (NOPAT 465.1m / Invested Capital 10.78b)
WACC = 7.69% (E(16.03b)/V(18.82b) * Re(8.91%) + D(2.78b)/V(18.82b) * Rd(0.88%) * (1-Tc(0.28)))
Discount Rate = 8.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF Debug] Terminal Value 76.86% ; FCFF base≈375.5m ; Y1≈321.2m ; Y5≈249.0m
Fair Price DCF = 10.90 (EV 4.81b - Net Debt 2.67b = Equity 2.14b / Shares 196.0m; r=7.69% [WACC]; 5y FCF grow -17.55% → 2.90% )
EPS Correlation: -84.43 | EPS CAGR: -59.55% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.26 | Revenue CAGR: 8.40% | SUE: 0.30 | # QB: 0
EPS next Quarter (2026-04-30): EPS=1.07 | Chg30d=-0.001 | Revisions Net=+1 | Analysts=17
EPS current Year (2026-10-31): EPS=4.51 | Chg30d=-0.001 | Revisions Net=+1 | Growth EPS=+9.4% | Growth Revenue=+5.5%
EPS next Year (2027-10-31): EPS=4.96 | Chg30d=+0.013 | Revisions Net=+2 | Growth EPS=+10.0% | Growth Revenue=+5.4%